Hi,I'm not the one answering your question, but the company did,...

Hi,
I'm not the one answering your question, but the company did, when Pitt was first announced to the market.It's the key to the study that only a big pharma (or an ambitious small/medium-sized company like Acadia) can accomplish.

Neuren (NEU) - ASX Announcement 17 May 2019NNZ-2591 demonstrates positive effects in Pitt Hopkins syndrome pre-clinical modelMelbourne, Australia, 17 May 2019: Neuren Pharmaceuticals (ASX: NEU) today announced thattreatment with its drug candidate NNZ-2591 has normalized all deficits in a pre-clinical model of theneurodevelopmental disorder Pitt Hopkins syndrome (PTHS). Neuren anticipates that PTHS meets thecriteria for Orphan Drug designation. There is currently no treatment specifically for PTHS.Characteristics of Pitt Hopkins syndrome (PTHS) are developmental delay with moderate-to-severeintellectual disability and behavioral differences, hyperventilation and/or breath-holding while awake,seizures, gastrointestinal issues, lack of speech, sleep disturbance, stereotypic hand movements anddistinctive facial features. Some individuals with PTHS are diagnosed with autism.